<DOC>
	<DOCNO>NCT00086463</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Iloprost subject Pulmonary Arterial Hypertension concurrently take bosentan ( Tracleer TM ) .</brief_summary>
	<brief_title>Trial Iloprost Inhaled Solution Add-On Therapy With Bosentan Subjects With Pulmonary Arterial Hypertension ( PAH )</brief_title>
	<detailed_description>This randomize , placebo-controlled study subject Pulmonary Arterial Hypertension ( PAH ) NYHA Class III IV receive conventional therapy bosentan . Subjects fulfill inclusion exclusion criterion randomize study drug ( active placebo ) frequency 6-9 inhalation per day 12 week continue conventional therapy bosentan . At end double-blind phase study , open label Iloprost provide .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Diagnosis PAH due PPH , connective tissue disease , HIV , repair ( â‰¥ 1 year ) ASD , VSD , PDA NYHA Functional Class III IV On bosentan least 16 week , dose stable ( maximum dose 125 mg BID ) least 8 week Age 1275 year , either gender Six minute walk distance 100425 meter Baseline Any new longterm treatment PAH add within last 4 week Any therapy PDE ( phosphodiesterase ) , L arginine prostaglandin , concurrently , within last 4 week PAH relate chronic thromboembolic disease , portopulmonary disease , etiology PPH , connective tissue disease , HIV , repair ASD , VSD , PDA</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>STEP</keyword>
	<keyword>PAH</keyword>
	<keyword>iloprost</keyword>
	<keyword>inhalation</keyword>
	<keyword>prostacyclin</keyword>
</DOC>